메뉴 건너뛰기
Clinical Reviews in Allergy and Immunology
Volumn 37, Issue 2, 2009, Pages 125-134
Management of haemophilia a-inhibitor patients: Clinical and regulatory perspectives
Author keywords

Clinical management; FVIII inhibitors; Haemophilia A; Regulatory issues
Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8A; DESMOPRESSIN; EMOCLOT; FVIII LFB; PHOSPHOLIPID; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;
EID: 70349264341     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-009-8115-4     Document Type: Review
Times cited : (8)
References (88)
  • 3
    • 0027250069 scopus 로고
    • 7691236 1:CAS:528:DyaK3sXms1yrsr8%3D
    • D Scandella M Mattingly R Prescott 1993 Blood 82 1767 1775 7691236 1:CAS:528:DyaK3sXms1yrsr8%3D
    • (1993) Blood , vol.82 , pp. 1767-1775
    • Scandella, D.1    Mattingly, M.2    Prescott, R.3
  • 14
    • 0024328077 scopus 로고
    • 2498393 10.1172/JCI114107 1:CAS:528:DyaL1MXksFejtbo%3D
    • M Arai D Scandella LW Hoyer 1989 J Clin Invest 83 1978 1984 2498393 10.1172/JCI114107 1:CAS:528:DyaL1MXksFejtbo%3D
    • (1989) J Clin Invest , vol.83 , pp. 1978-1984
    • Arai, M.1    Scandella, D.2    Hoyer, L.W.3
  • 20
    • 17944404210 scopus 로고    scopus 로고
    • Safety and efficacy of KOGENATE® Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs)
    • DOI 10.1046/j.1351-8216.2001.00133.x
    • PL Giangrande 2002 Haemophilia 8 Suppl 2 19 22 11966848 10.1046/j.1351-8216.2001.00133.x 1:CAS:528:DC%2BD38XksFSluro%3D (Pubitemid 34498624)
    • (2002) Haemophilia , vol.8 , Issue.SUPPL. 2 , pp. 19-22
    • Giangrande, P.L.F.1
  • 23
    • 0037810801 scopus 로고    scopus 로고
    • 12828677 10.1046/j.1365-2516.2003.00779.x 1:CAS:528:DC%2BD3sXmsFGisbw%3D
    • S Paisley J Wight E Currie C Knight 2003 Haemophilia 9 405 417 12828677 10.1046/j.1365-2516.2003.00779.x 1:CAS:528:DC%2BD3sXmsFGisbw%3D
    • (2003) Haemophilia , vol.9 , pp. 405-417
    • Paisley, S.1    Wight, J.2    Currie, E.3    Knight, C.4
  • 26
    • 33646686129 scopus 로고    scopus 로고
    • The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organisation
    • DOI 10.1111/j.1365-2141.2006.06087.x
    • CR Hay S Brown PW Collins DM Keeling R Liesner 2006 Br J Haematol 133 591 605 16704433 10.1111/j.1365-2141.2006.06087.x 1:CAS:528:DC%2BD28XmslCrs78%3D (Pubitemid 43742773)
    • (2006) British Journal of Haematology , vol.133 , Issue.6 , pp. 591-605
    • Hay, C.R.M.1    Brown, S.2    Collins, P.W.3    Keeling, D.M.4    Liesner, R.5
  • 27
    • 0033768130 scopus 로고    scopus 로고
    • The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO)
    • DOI 10.1046/j.1365-2141.2000.02327.x
    • CR Hay TP Baglin PW Collins FG Hill DM Keeling 2000 Br J Haematol 111 78 90 11091185 10.1046/j.1365-2141.2000.02327.x 1:STN:280:DC%2BD3M%2FltFantw%3D%3D (Pubitemid 30832435)
    • (2000) British Journal of Haematology , vol.111 , Issue.1 , pp. 78-90
    • Hay, C.R.M.1    Baglin, T.P.2    Collins, P.W.3    Hill, F.G.H.4    Keeling, D.M.5
  • 28
    • 33750796998 scopus 로고    scopus 로고
    • Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy
    • DOI 10.1111/j.1365-2516.2006.01338.x
    • K Peerlinck C Hermans 2006 Haemophilia 12 579 590 17083507 10.1111/j.1365-2516.2006.01338.x 1:CAS:528:DC%2BD2sXhtFKgtA%3D%3D (Pubitemid 44710297)
    • (2006) Haemophilia , vol.12 , Issue.6 , pp. 579-590
    • Peerlinck, K.1    Hermans, C.2
  • 29
    • 0038383605 scopus 로고    scopus 로고
    • 12828678 10.1046/j.1365-2516.2003.00780.x 1:STN:280: DC%2BD3szgtFKhtA%3D%3D
    • J Wight S Paisley 2003 Haemophilia 9 418 435 12828678 10.1046/j.1365-2516.2003.00780.x 1:STN:280:DC%2BD3szgtFKhtA%3D%3D
    • (2003) Haemophilia , vol.9 , pp. 418-435
    • Wight, J.1    Paisley, S.2
  • 30
    • 2942620820 scopus 로고    scopus 로고
    • Systematic review of the management of patients with haemophilia A and inhibitors
    • DOI 10.1097/00001721-200405001-00005
    • M Makris 2004 Blood Coagul Fibrinolysis 15 Suppl 1 S25 S27 15166930 10.1097/00001721-200405001-00005 1:CAS:528:DC%2BD2cXkvVOhs70%3D (Pubitemid 38757072)
    • (2004) Blood Coagulation and Fibrinolysis , vol.15 , Issue.SUPPL. 1
    • Makris, M.1
  • 31
    • 0035085357 scopus 로고    scopus 로고
    • Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients
    • DOI 10.1046/j.1365-2516.2001.00482.x
    • CS Philipp 2001 Haemophilia 7 146 153 11260273 10.1046/j.1365-2516.2001. 00482.x 1:CAS:528:DC%2BD3MXnsFWgurc%3D (Pubitemid 32243796)
    • (2001) Haemophilia , vol.7 , Issue.2 , pp. 146-153
    • Philipp, C.S.1
  • 34
    • 34249711370 scopus 로고    scopus 로고
    • Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: The CANAL cohort study
    • DOI 10.1182/blood-2006-11-056317
    • SC Gouw JG van der Bom G Auerswald CE Ettinghausen U Tedgard HM van den Berg 2007 Blood 109 4693 4697 17218379 10.1182/blood-2006-11-056317 1:CAS:528:DC%2BD2sXmt1OgtLk%3D (Pubitemid 46827760)
    • (2007) Blood , vol.109 , Issue.11 , pp. 4693-4697
    • Gouw, S.C.1    Van Der Bom, J.G.2    Auerswald, G.3    Ettinghausen, C.E.4    Tedgard, U.5    Van Den Berg, H.M.6
  • 36
    • 33751010515 scopus 로고    scopus 로고
    • Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development
    • DOI 10.1111/j.1365-2516.2006.01373.x
    • CE Ettingshausen W Kreuz 2006 Haemophilia 12 Suppl 6 102 106 17123402 10.1111/j.1365-2516.2006.01373.x (Pubitemid 44741510)
    • (2006) Haemophilia , vol.12 , Issue.SUPPL. 6 , pp. 102-106
    • Ettingshausen, C.E.1    Kreuz, W.2
  • 42
    • 33845239946 scopus 로고    scopus 로고
    • Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
    • DOI 10.1182/blood-2006-05-024711
    • J Astermark J Oldenburg J Carlson A Pavlova K Kavakli E Berntorp AK Lefvert 2006 Blood 108 3739 3745 16926287 10.1182/blood-2006-05-024711 1:CAS:528:DC%2BD28Xht1Kgs7%2FF (Pubitemid 44864553)
    • (2006) Blood , vol.108 , Issue.12 , pp. 3739-3745
    • Astermark, J.1    Oldenburg, J.2    Carlson, J.3    Pavlova, A.4    Kavakli, K.5    Berntorp, E.6    Lefvert, A.-K.7
  • 43
    • 0033832945 scopus 로고    scopus 로고
    • 11012709 10.1046/j.1365-2516.2000.00451.x 1:STN:280: DC%2BD3M%2FksFaqsw%3D%3D
    • TT Yee CA Lee 2000 Haemophilia 6 591 11012709 10.1046/j.1365-2516.2000. 00451.x 1:STN:280:DC%2BD3M%2FksFaqsw%3D%3D
    • (2000) Haemophilia , vol.6 , pp. 591
    • Yee, T.T.1    Lee, C.A.2
  • 45
    • 34249690732 scopus 로고    scopus 로고
    • Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study
    • DOI 10.1182/blood-2006-11-056291
    • SC Gouw JG van der Bom BH Marijke van den 2007 Blood 109 4648 4654 17289808 10.1182/blood-2006-11-056291 1:CAS:528:DC%2BD2sXmt1OgtL8%3D (Pubitemid 46827754)
    • (2007) Blood , vol.109 , Issue.11 , pp. 4648-4654
    • Gouw, S.C.1    Van Der Bom, J.G.2    Van Den Berg, H.M.3
  • 46
    • 33845485057 scopus 로고    scopus 로고
    • Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors
    • DOI 10.1111/j.1365-2141.2006.06359.x
    • BM Reipert PM van Helden HP Schwarz C Hausl 2007 Br J Haematol 136 12 25 17222196 10.1111/j.1365-2141.2006.06359.x 1:CAS:528:DC%2BD2sXisVKisbk%3D (Pubitemid 44912584)
    • (2007) British Journal of Haematology , vol.136 , Issue.1 , pp. 12-25
    • Reipert, B.M.1    Van Helden, P.M.2    Schwarz, H.-P.3    Hausl, C.4
  • 48
    • 0030056318 scopus 로고    scopus 로고
    • 8869466 10.1111/j.1423-0410.1996.tb01346.x
    • HH Brackmann J Oldenburg R Schwaab 1996 Vox Sang 70 Suppl 1 30 35 8869466 10.1111/j.1423-0410.1996.tb01346.x
    • (1996) Vox Sang , vol.70 , Issue.SUPPL. 1 , pp. 30-35
    • Brackmann, H.H.1    Oldenburg, J.2    Schwaab, R.3
  • 50
    • 0026571955 scopus 로고
    • 1550269 10.1097/00043426-199221000-00013 1:STN:280:DyaK387pslygsA%3D%3D
    • RA Gruppo LP Valdez RD Stout 1992 Am J Pediatr Hematol Oncol 14 82 87 1550269 10.1097/00043426-199221000-00013 1:STN:280:DyaK387pslygsA%3D%3D
    • (1992) Am J Pediatr Hematol Oncol , vol.14 , pp. 82-87
    • Gruppo, R.A.1    Valdez, L.P.2    Stout, R.D.3
  • 52
    • 0035135212 scopus 로고    scopus 로고
    • Immune tolerance induction in haemophilia a patients with high-responding inhibitors to factor VIII: Experience at a single institution
    • DOI 10.1046/j.1365-2516.2001.00461.x
    • A Rocino ML Papa E Salerno F Capasso E Miraglia R de Biasi 2001 Haemophilia 7 33 38 11136378 10.1046/j.1365-2516.2001.00461.x 1:CAS:528:DC%2BD3MXnsFWgtbw%3D (Pubitemid 32162195)
    • (2001) Haemophilia , vol.7 , Issue.1 , pp. 33-38
    • Rocino, A.1    Papa, M.L.2    Salerno, E.3    Capasso, F.4    Miraglia, E.5    De Biasi, R.6
  • 55
    • 0033678959 scopus 로고    scopus 로고
    • 11187870 1:CAS:528:DC%2BD3cXptVegsLg%3D
    • H Lenk 2000 Haematologica 85 45 47 11187870 1:CAS:528: DC%2BD3cXptVegsLg%3D
    • (2000) Haematologica , vol.85 , pp. 45-47
    • Lenk, H.1
  • 57
    • 0036147943 scopus 로고    scopus 로고
    • 11848456 1:CAS:528:DC%2BD38XhtV2ju74%3D
    • DM Dimichele BL Kroner 2002 Thromb Haemost 87 52 57 11848456 1:CAS:528:DC%2BD38XhtV2ju74%3D
    • (2002) Thromb Haemost , vol.87 , pp. 52-57
    • Dimichele, D.M.1    Kroner, B.L.2
  • 59
    • 33748743730 scopus 로고    scopus 로고
    • The international immune tolerance study: A multicenter prospective randomized trial in progress [2]
    • DOI 10.1111/j.1538-7836.2006.02127.x
    • DM Dimichele CR Hay 2006 J Thromb Haemost 4 2271 2273 16848866 10.1111/j.1538-7836.2006.02127.x 1:STN:280:DC%2BD28rntFOltA%3D%3D (Pubitemid 44400309)
    • (2006) Journal of Thrombosis and Haemostasis , vol.4 , Issue.10 , pp. 2271-2273
    • Dimichele, D.M.1    Hay, C.R.M.2
  • 60
    • 37149006720 scopus 로고    scopus 로고
    • 18078402 1:CAS:528:DC%2BD1cXhs1ylu78%3D
    • A Gringeri 2007 Haemophilia 13 Suppl 5 73 77 18078402 1:CAS:528:DC%2BD1cXhs1ylu78%3D
    • (2007) Haemophilia , vol.13 , Issue.SUPPL. 5 , pp. 73-77
    • Gringeri, A.1
  • 64
    • 0034917040 scopus 로고    scopus 로고
    • Von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients
    • DOI 10.1046/j.1365-2516.2001.00530.x
    • A Kallas T Talpsep 2001 Haemophilia 7 375 380 11442642 10.1046/j.1365-2516.2001.00530.x 1:CAS:528:DC%2BD3MXnsFWns7w%3D (Pubitemid 32677656)
    • (2001) Haemophilia , vol.7 , Issue.4 , pp. 375-380
    • Kallas, A.1    Talpsep, R.2
  • 70
    • 0642372623 scopus 로고    scopus 로고
    • 12871449 10.1046/j.1538-7836.2003.00059.x 1:CAS:528:DC%2BD2cXktFentbk%3D
    • G Kenet A Lubetsky J Luboshitz U Martinowitz 2003 J Thromb Haemost 1 450 455 12871449 10.1046/j.1538-7836.2003.00059.x 1:CAS:528:DC%2BD2cXktFentbk%3D
    • (2003) J Thromb Haemost , vol.1 , pp. 450-455
    • Kenet, G.1    Lubetsky, A.2    Luboshitz, J.3    Martinowitz, U.4
  • 71
    • 33846185403 scopus 로고    scopus 로고
    • A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) study
    • DOI 10.1182/blood-2006-04-017988
    • J Astermark SM Donfield DM Dimichele A Gringeri SA Gilbert J Waters E Berntorp 2007 Blood 109 546 551 16990605 10.1182/blood-2006-04-017988 1:CAS:528:DC%2BD2sXivVyku7g%3D (Pubitemid 46105952)
    • (2007) Blood , vol.109 , Issue.2 , pp. 546-551
    • Astermark, J.1    Donfield, S.M.2    DiMichele, D.M.3    Gringeri, A.4    Gilbert, S.A.5    Waters, J.6    Berntorp, E.7
  • 72
    • 2942591961 scopus 로고    scopus 로고
    • Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia
    • DOI 10.1182/blood-2003-11-4075
    • R Stasi M Brunetti E Stipa S Amadori 2004 Blood 103 4424 4428 14996701 10.1182/blood-2003-11-4075 1:CAS:528:DC%2BD2cXlt1KrsLc%3D (Pubitemid 38745966)
    • (2004) Blood , vol.103 , Issue.12 , pp. 4424-4428
    • Stasi, R.1    Brunetti, M.2    Stipa, E.3    Amadori, S.4
  • 73
    • 2442472195 scopus 로고    scopus 로고
    • Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia
    • DOI 10.1111/j.1365-2141.2004.04916.x
    • M Mathias K Khair I Hann R Liesner 2004 Br J Haematol 125 366 368 15086418 10.1111/j.1365-2141.2004.04916.x (Pubitemid 38621768)
    • (2004) British Journal of Haematology , vol.125 , Issue.3 , pp. 366-368
    • Mathias, M.1    Khair, K.2    Hann, I.3    Liesner, R.4
  • 77
    • 33750974213 scopus 로고    scopus 로고
    • Immune tolerance: Critical issues of factor dose, purity and treatment complications
    • DOI 10.1111/j.1365-2516.2006.01376.x
    • DM Dimichele 2006 Haemophilia 12 Suppl 6 81 85 17123399 10.1111/j.1365-2516.2006.01376.x (Pubitemid 44741507)
    • (2006) Haemophilia , vol.12 , Issue.SUPPL. 6 , pp. 81-86
    • Dimichele, D.M.1
  • 78
    • 34250708408 scopus 로고    scopus 로고
    • Treatment characteristics and the risk of inhibitor development: A multicenter cohort study among previously untreated patients with severe hemophilia A
    • DOI 10.1111/j.1538-7836.2007.02595.x
    • SC Gouw HM van den Berg S le Cessie JG van der Bom 2007 J Thromb Haemost 5 1383 1390 17456190 10.1111/j.1538-7836.2007.02595.x 1:CAS:528: DC%2BD2sXovVOmsr8%3D (Pubitemid 46965364)
    • (2007) Journal of Thrombosis and Haemostasis , vol.5 , Issue.7 , pp. 1383-1390
    • Gouw, S.C.1    Van Den Berg, H.M.2    Le Cessie, S.3    Van Der Bom, J.G.4
  • 79
    • 19444363534 scopus 로고    scopus 로고
    • The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: An update [2]
    • DOI 10.1111/j.1365-2516.2005.01099.x
    • JM Lusher DA Roth 2005 Haemophilia 11 292 293 15876278 10.1111/j.1365-2516.2005.01099.x 1:CAS:528:DC%2BD2MXlsFSks7s%3D (Pubitemid 40723808)
    • (2005) Haemophilia , vol.11 , Issue.3 , pp. 292-293
    • Lusher, J.M.1    Roth, D.A.2
  • 87
    • 0027257566 scopus 로고
    • Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
    • DOI 10.1016/0140-6736(93)91593-B
    • J Addiego C Kasper C Abildgaard M Hilgartner J Lusher B Glader L Aledort 1993 Lancet 342 462 464 8102429 10.1016/0140-6736(93)91593-B 1:STN:280:DyaK3szltl2ltw%3D%3D (Pubitemid 23240310)
    • (1993) Lancet , vol.342 , Issue.8869 , pp. 462-464
    • Addiego, J.1    Kasper, C.2    Abildgaard, C.3    Hilgartner, M.4    Lusher, J.5    Glader, B.6    Aledort, L.7

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.